Selected research
Industry Growth & Trends
Global Personalized Radioimmunotherapy Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Personalized Radioimmunotherapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Personalized Radioimmunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Personalized Radioimmunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Personalized Radioimmunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Personalized Radioimmunotherapy market include Novartis, Bayer, Y-mAbs Therapeutics, Telix Pharmaceuticals, RadioMedix, Philogen, Orano Med, Nordic Nanovector and Mundipharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Personalized Radioimmunotherapy market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Personalized Radioimmunotherapy market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Personalized Radioimmunotherapy market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Personalized Radioimmunotherapy.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Personalized Radioimmunotherapy market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Personalized Radioimmunotherapy Market by Company
Novartis
Bayer
Y-mAbs Therapeutics
Telix Pharmaceuticals
RadioMedix
Philogen
Orano Med
Nordic Nanovector
Mundipharma
Lantheus
Gilead Sciences
Fusion Pharmaceuticals
Curium Pharmaceuticals
Curasight
Clarity Pharmaceuticals
China Isotope & Radiation
Aurobindo Pharma
Actinium Pharmaceuticals
Personalized Radioimmunotherapy Segment by Type
Beta-emitting
Targeted Alpha Therapy
Personalized Radioimmunotherapy Segment by Application
Solid Tumor
Non Hodgkin Lymphoma
Personalized Radioimmunotherapy Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Personalized Radioimmunotherapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Personalized Radioimmunotherapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Personalized Radioimmunotherapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Personalized Radioimmunotherapy companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Beta-emitting
- Targeted Alpha Therapy
Applications
- Solid Tumor
- Non Hodgkin Lymphoma
Companies covered
- Novartis
- Bayer
- Y-mAbs Therapeutics
- Telix Pharmaceuticals
- RadioMedix
- Philogen
- Orano Med
- Nordic Nanovector
- Mundipharma
- Lantheus
- Gilead Sciences
- Fusion Pharmaceuticals
- Curium Pharmaceuticals
- Curasight
- Clarity Pharmaceuticals
- China Isotope & Radiation
- Aurobindo Pharma
- Actinium Pharmaceuticals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Personalized Radioimmunotherapy Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Personalized Radioimmunotherapy Market Size by Region (2021-2032)
- 1.4.1 Global Personalized Radioimmunotherapy Market Size by Region (2021-2026)
- 1.4.2 Global Personalized Radioimmunotherapy Market Size by Region (2027-2032)
- 1.5 Key Regions Personalized Radioimmunotherapy Market Size (2021-2032)
- 1.5.1 North America Personalized Radioimmunotherapy Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Personalized Radioimmunotherapy Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Personalized Radioimmunotherapy Market Size Growth Rate (2021-2032)
- 1.5.4 South America Personalized Radioimmunotherapy Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Personalized Radioimmunotherapy Market Size Growth Rate (2021-2032)
2 Personalized Radioimmunotherapy Market by Type
- 2.1 Type Introduction
- 2.1.1 Beta-emitting
- 2.1.2 Targeted Alpha Therapy
- 2.2 Global Personalized Radioimmunotherapy Market Size by Type
- 2.2.1 Global Personalized Radioimmunotherapy Market Size Overview by Type (2021-2032)
- 2.2.2 Global Personalized Radioimmunotherapy Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Personalized Radioimmunotherapy Market Size Forecasted by Type (2027-2032)
- 2.3 Global Personalized Radioimmunotherapy Market Size by Regions
- 2.3.1 North America Personalized Radioimmunotherapy Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Personalized Radioimmunotherapy Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Personalized Radioimmunotherapy Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Personalized Radioimmunotherapy Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Personalized Radioimmunotherapy Market Size Breakdown by Type (2021-2026)
3 Personalized Radioimmunotherapy Market by Application
- 3.1 Type Introduction
- 3.1.1 Solid Tumor
- 3.1.2 Non Hodgkin Lymphoma
- 3.2 Global Personalized Radioimmunotherapy Market Size by Application
- 3.2.1 Global Personalized Radioimmunotherapy Market Size Overview by Application (2021-2032)
- 3.2.2 Global Personalized Radioimmunotherapy Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Personalized Radioimmunotherapy Market Size Forecasted by Application (2027-2032)
- 3.3 Global Personalized Radioimmunotherapy Market Size by Regions
- 3.3.1 North America Personalized Radioimmunotherapy Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Personalized Radioimmunotherapy Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Personalized Radioimmunotherapy Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Personalized Radioimmunotherapy Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Personalized Radioimmunotherapy Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Personalized Radioimmunotherapy Industry Trends
- 4.2 Personalized Radioimmunotherapy Industry Drivers
- 4.3 Personalized Radioimmunotherapy Industry Opportunities and Challenges
- 4.4 Personalized Radioimmunotherapy Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Personalized Radioimmunotherapy Revenue (2021-2026)
- 5.2 Global Personalized Radioimmunotherapy Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Personalized Radioimmunotherapy Key Company Headquarters & Area Served
- 5.4 Global Personalized Radioimmunotherapy Company, Product Type & Application
- 5.5 Global Personalized Radioimmunotherapy Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Personalized Radioimmunotherapy Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Personalized Radioimmunotherapy Players Market Share by Revenue in 2025
- 5.6.3 2025 Personalized Radioimmunotherapy Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Novartis
- 6.1.1 Novartis Company Information
- 6.1.2 Novartis Business Overview
- 6.1.3 Novartis Personalized Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Novartis Personalized Radioimmunotherapy Product Portfolio
- 6.1.5 Novartis Recent Developments
- 6.2 Bayer
- 6.2.1 Bayer Company Information
- 6.2.2 Bayer Business Overview
- 6.2.3 Bayer Personalized Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Bayer Personalized Radioimmunotherapy Product Portfolio
- 6.2.5 Bayer Recent Developments
- 6.3 Y-mAbs Therapeutics
- 6.3.1 Y-mAbs Therapeutics Company Information
- 6.3.2 Y-mAbs Therapeutics Business Overview
- 6.3.3 Y-mAbs Therapeutics Personalized Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Y-mAbs Therapeutics Personalized Radioimmunotherapy Product Portfolio
- 6.3.5 Y-mAbs Therapeutics Recent Developments
- 6.4 Telix Pharmaceuticals
- 6.4.1 Telix Pharmaceuticals Company Information
- 6.4.2 Telix Pharmaceuticals Business Overview
- 6.4.3 Telix Pharmaceuticals Personalized Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Telix Pharmaceuticals Personalized Radioimmunotherapy Product Portfolio
- 6.4.5 Telix Pharmaceuticals Recent Developments
- 6.5 RadioMedix
- 6.5.1 RadioMedix Company Information
- 6.5.2 RadioMedix Business Overview
- 6.5.3 RadioMedix Personalized Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 RadioMedix Personalized Radioimmunotherapy Product Portfolio
- 6.5.5 RadioMedix Recent Developments
- 6.6 Philogen
- 6.6.1 Philogen Company Information
- 6.6.2 Philogen Business Overview
- 6.6.3 Philogen Personalized Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Philogen Personalized Radioimmunotherapy Product Portfolio
- 6.6.5 Philogen Recent Developments
- 6.7 Orano Med
- 6.7.1 Orano Med Company Information
- 6.7.2 Orano Med Business Overview
- 6.7.3 Orano Med Personalized Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Orano Med Personalized Radioimmunotherapy Product Portfolio
- 6.7.5 Orano Med Recent Developments
- 6.8 Nordic Nanovector
- 6.8.1 Nordic Nanovector Company Information
- 6.8.2 Nordic Nanovector Business Overview
- 6.8.3 Nordic Nanovector Personalized Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Nordic Nanovector Personalized Radioimmunotherapy Product Portfolio
- 6.8.5 Nordic Nanovector Recent Developments
- 6.9 Mundipharma
- 6.9.1 Mundipharma Company Information
- 6.9.2 Mundipharma Business Overview
- 6.9.3 Mundipharma Personalized Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Mundipharma Personalized Radioimmunotherapy Product Portfolio
- 6.9.5 Mundipharma Recent Developments
- 6.10 Lantheus
- 6.10.1 Lantheus Company Information
- 6.10.2 Lantheus Business Overview
- 6.10.3 Lantheus Personalized Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Lantheus Personalized Radioimmunotherapy Product Portfolio
- 6.10.5 Lantheus Recent Developments
- 6.11 Gilead Sciences
- 6.11.1 Gilead Sciences Company Information
- 6.11.2 Gilead Sciences Business Overview
- 6.11.3 Gilead Sciences Personalized Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Gilead Sciences Personalized Radioimmunotherapy Product Portfolio
- 6.11.5 Gilead Sciences Recent Developments
- 6.12 Fusion Pharmaceuticals
- 6.12.1 Fusion Pharmaceuticals Company Information
- 6.12.2 Fusion Pharmaceuticals Business Overview
- 6.12.3 Fusion Pharmaceuticals Personalized Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Fusion Pharmaceuticals Personalized Radioimmunotherapy Product Portfolio
- 6.12.5 Fusion Pharmaceuticals Recent Developments
- 6.13 Curium Pharmaceuticals
- 6.13.1 Curium Pharmaceuticals Company Information
- 6.13.2 Curium Pharmaceuticals Business Overview
- 6.13.3 Curium Pharmaceuticals Personalized Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Curium Pharmaceuticals Personalized Radioimmunotherapy Product Portfolio
- 6.13.5 Curium Pharmaceuticals Recent Developments
- 6.14 Curasight
- 6.14.1 Curasight Company Information
- 6.14.2 Curasight Business Overview
- 6.14.3 Curasight Personalized Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Curasight Personalized Radioimmunotherapy Product Portfolio
- 6.14.5 Curasight Recent Developments
- 6.15 Clarity Pharmaceuticals
- 6.15.1 Clarity Pharmaceuticals Company Information
- 6.15.2 Clarity Pharmaceuticals Business Overview
- 6.15.3 Clarity Pharmaceuticals Personalized Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.15.4 Clarity Pharmaceuticals Personalized Radioimmunotherapy Product Portfolio
- 6.15.5 Clarity Pharmaceuticals Recent Developments
- 6.16 China Isotope & Radiation
- 6.16.1 China Isotope & Radiation Company Information
- 6.16.2 China Isotope & Radiation Business Overview
- 6.16.3 China Isotope & Radiation Personalized Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.16.4 China Isotope & Radiation Personalized Radioimmunotherapy Product Portfolio
- 6.16.5 China Isotope & Radiation Recent Developments
- 6.17 Aurobindo Pharma
- 6.17.1 Aurobindo Pharma Company Information
- 6.17.2 Aurobindo Pharma Business Overview
- 6.17.3 Aurobindo Pharma Personalized Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.17.4 Aurobindo Pharma Personalized Radioimmunotherapy Product Portfolio
- 6.17.5 Aurobindo Pharma Recent Developments
- 6.18 Actinium Pharmaceuticals
- 6.18.1 Actinium Pharmaceuticals Company Information
- 6.18.2 Actinium Pharmaceuticals Business Overview
- 6.18.3 Actinium Pharmaceuticals Personalized Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.18.4 Actinium Pharmaceuticals Personalized Radioimmunotherapy Product Portfolio
- 6.18.5 Actinium Pharmaceuticals Recent Developments
7 North America
- 7.1 North America Personalized Radioimmunotherapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Personalized Radioimmunotherapy Market Size by Country (2021-2026)
- 7.3 North America Personalized Radioimmunotherapy Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Personalized Radioimmunotherapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Personalized Radioimmunotherapy Market Size by Country (2021-2026)
- 8.3 Europe Personalized Radioimmunotherapy Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Personalized Radioimmunotherapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Personalized Radioimmunotherapy Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Personalized Radioimmunotherapy Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Personalized Radioimmunotherapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Personalized Radioimmunotherapy Market Size by Country (2021-2026)
- 10.3 South America Personalized Radioimmunotherapy Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Personalized Radioimmunotherapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Personalized Radioimmunotherapy Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Personalized Radioimmunotherapy Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst